To the full analysis
Xenon Pharmaceuticals stock: growth
XENEGrowth only counts when it reaches the bottom line. That is why revenue, earnings and free cash flow for Xenon Pharmaceuticals Inc. stand side by side here: revenue growing faster than earnings is growth that was bought.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
0.6%
per year from 2011 to 2025, per share −24.9%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2011 | |
|---|---|---|---|
| Revenue | −25.3% | −7.0% | 0.6% |
| Revenue per share | −36.7% | −21.7% | −24.9% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2011 | $6.92M | −$11.99M | −$13.98M |
| 2012 | $14.31M | −$4.3M | $45.05M |
| 2013 | $27.36M | $12.03M | −$3.48M |
| 2014 | $28.37M | $13.02M | −$1.26M |
| 2015 | $15.58M | −$15.75M | −$18.65M |
| 2016 | $1.8M | −$23M | −$19.85M |
| 2017 | $311K | −$30.7M | −$29.04M |
| 2018 | $0 | −$34.5M | −$35.23M |
| 2019 | $6.83M | −$41.6M | −$5.87M |
| 2020 | $32.17M | −$28.84M | −$50.76M |
| 2021 | $18.44M | −$78.88M | −$71.55M |
| 2022 | $9.43M | −$125.37M | −$101.32M |
| 2023 | $0 | −$182.39M | −$150.94M |
| 2024 | $0 | −$234.33M | −$184.46M |
| 2025 | $7.5M | −$345.91M | −$279.92M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Nov 2015)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.